The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
about
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense MutationsPharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.E-Learning for Rare Diseases: An Example Using Fabry Disease.Low frequency of Fabry disease in patients with common heart disease.Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
P2860
Q33886219-9DB43FEE-2D44-47BE-9507-EEFBC5D62C0FQ36213022-8DD0D57B-B984-4000-9112-921A6F239E3FQ38652950-66658ABC-D538-46A0-B67A-798718226DDDQ47144777-30CA9AE4-3D11-4864-A9F8-18AAF3CF308CQ47147113-BC5F7208-0C8A-4739-B9D4-C11131767F53Q49941415-1229BC09-03C6-4614-8ED8-24397D3EBA4EQ51842157-30C305A4-EEA4-4761-8F87-CDC4094441C9Q55383790-2CA1E118-0077-47CF-BE4E-57200F06B621Q58794894-E9DD9A1C-52A2-4B2B-BC94-855949914248
P2860
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The validation of pharmacogene ...... to be treated with migalastat
@ast
The validation of pharmacogene ...... to be treated with migalastat
@en
The validation of pharmacogene ...... to be treated with migalastat.
@nl
type
label
The validation of pharmacogene ...... to be treated with migalastat
@ast
The validation of pharmacogene ...... to be treated with migalastat
@en
The validation of pharmacogene ...... to be treated with migalastat.
@nl
prefLabel
The validation of pharmacogene ...... to be treated with migalastat
@ast
The validation of pharmacogene ...... to be treated with migalastat
@en
The validation of pharmacogene ...... to be treated with migalastat.
@nl
P2093
P2860
P50
P356
P1433
P1476
The validation of pharmacogene ...... to be treated with migalastat
@en
P2093
Benjamin Bronfin
Carrolee Barlow
Elfrida R Benjamin
Farhana Pruthi
Kenneth J Valenzano
Raphael Schiffmann
Robert J Desnick
P2860
P2888
P304
P356
10.1038/GIM.2016.122
P407
P50
P577
2016-09-22T00:00:00Z